Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post‐STAMPEDE world

No abstract is available for this paper.

• Publication year

  2017

• Venue

  BJU International

• Publication date

  2017-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bju.13990PMID 28834013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results

  2017cited by this paper
• Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

  2016cited by this paper
• Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

  2016cited by this paper
• Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly.

  2016cited by this paper
• Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly

  2015cited by this paper
• Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

  2015cited by this paper
• Trends in the treatment of localized prostate cancer using supplemented cancer registry data

  2011cited by this paper
• The prognostic index.

  1952cited by this paper

• Obesity and low levels of physical activity impact on cardiopulmonary fitness in older men after treatment for prostate cancer.

  2021cites this paper
• Efficacy and toxicity outcomes of elderly castrate-resistant prostate cancer patients treated with docetaxel-A pooled analysis of 3 randomized studies.

  2020cites this paper
• Risk Assessment and Considerations for Proper Management of Elderly Men with Advanced Prostate Cancer: A Systematic Review.

  2020cites this paper
• Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer

  2020cites this paper
• A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control

  2019cites this paper
• Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.

  2019cites this paper
• Improving Outcomes in Prostate Cancer

  2019cites this paper
• The Siconolfi step test: a valid and reliable assessment of cardiopulmonary fitness in older men with prostate cancer

  2019cites this paper